The interference peptides (EN1-iPeps) that selectively inhibit EN1 activity can be used for the treatment of aggressive basal-like triple negative breast carcinomas (Gandhi, Blancafort & Mancera, 2018). The gene discussed is EN1; the disease is triple-negative breast carcinoma.